Multi‐Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
Cancer Medicine · 2025
DOI: 10.1002/cam4.70676 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Fangdong Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laborator…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, The Construction Project of Cancer Precision Diagnosis and Drug Treatment Technology.
Abstract (Originalsprache)
Background
The recurrence patterns of different types of pathologic regression of the primary tumor and lymph nodes in patients with esophageal squamous cell carcinoma (ESCC) after neoadjuvant chemoradiotherapy (NCRT) are little known, especially in ypT0N+ patients.
Methods
We included 582 patients with ESCC who had esophagectomy after NCRT or neoadjuvant radiotherapy (NRT) from 3 institutions. The patients were divided into 4 groups: ypT0N0, ypT0N+, ypT+N0, and ypT+N+ according to the type of pathological regression of the primary tumor and lymph nodes. Survival, recurrence pattern and timing, and potential prognostic factors were compared.
Results
A total of 179 patients were classified as ypT0N0, 227 patients as ypT + N0, 45 patients as ypT0N+, and 131 patients as ypT + N+. The median follow‐up was 31.7 months in all patients. The restricted mean survival time (RMST) of ypT0N0, ypT + N0, ypT0N+, and ypT + N+ patients decreased sequentially (70.64, 63.84, 55.93 and 39.96 months) and the recurrence rates increased sequentially (22.3%, 29.5%, 44.4% and 54.2%). Both the overall survival (OS) and recurrence‐free survival (RFS) in the ypT0N+ group were significantly lower than those in the ypT0N0 group (HR: 2.226, p = 0.007; HR: 2.271, p = 0.003). The distant metastasis (DM) pattern in ypT0N+ was similar to that of ypT + N+, and higher than that of ypN0 (25.6% vs 14.3%, HR: 1.970, p = 0.040).
Conclusions
ESCC patients with various pathological regression types after receiving NCRT or NRT had significantly different survival rates. ypT0N+ patients had a lower survival rate and higher DM rate than ypT0N0 patients. For these lymph node‐positive patients, adjuvant chemotherapy does not appear to improve their prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center…
- Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichua…
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical…
- Department of Nutrition Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Cente…
- Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Cente…
ORCID-Profile: Weiming Han, Tian Zhang, Zefen Xiao, Ping Wang, Peng Tang
Förderung
- National Natural Science Foundation of China
- The Construction Project of Cancer Precision Diagnosis and Drug Treatment Technology
Zitieren
APA
Zhao, F., Wang, Q., Han, W., Maitudi, W., Cao, F., Zhang, T., Chen, X., Dong, J., Gong, L., Shang, X., Jiang, H., Zhang, W., Pang, Q., Xiao, Z., Wang, P., & Tang, P. (2025). Multi‐Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70676
Vancouver
Zhao F, Wang Q, Han W, Maitudi W, Cao F, Zhang T, et al. Multi‐Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.70676
BibTeX
@article{Zhao2025,
author = {Zhao, Fangdong and Wang, Qifeng and Han, Weiming and Maitudi, Wubulaishan and Cao, Fuliang and Zhang, Tian and Chen, Xi and Dong, Jie and Gong, Lei and Shang, Xiaobin and Jiang, Hongjing and Zhang, Wencheng and Pang, Qingsong and Xiao, Zefen and Wang, Ping and Tang, Peng},
title = {Multi‐Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70676}
}
EUVIMED